Machado-Joseph disease and other rare spinocerebellar ataxias

Advances in Experimental Medicine and Biology

Volumn 724, Issue , 2012, Pages 172-188

  Matilla Dueñas, Antoni ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; 5 HYDROXYTRYPTOPHAN; ACETAZOLAMIDE; AMANTADINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BUSPIRONE; CARBAMAZEPINE; CHAPERONE; CHLORZOXAZONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; COTRIMOXAZOLE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUNARIZINE; GABAPENTIN; LAMOTRIGINE; LITHIUM CARBONATE; MAGNESIUM; MEMANTINE; MEXILETINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUININE; TANDOSPIRONE; TIZANIDINE; UNINDEXED DRUG; VALPROIC ACID; VARENICLINE; ATXN3 PROTEIN, HUMAN; NERVE PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN;

ALLELE; ARTICLE; ATAXIA; AUTOSOMAL DOMINANT SPASTIC ATAXIA; BALANCE TRAINING; BRADYKINESIA; BRAIN DEPTH STIMULATION; CAG REPEAT; CLINICAL FEATURE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DYSTONIA; EARLY DIAGNOSIS; EPISODIC ATAXIA TYPE 1; EPISODIC ATAXIA TYPE 2; EPISODIC ATAXIA TYPE 3; EPISODIC ATAXIA TYPE 4; EPISODIC ATAXIA TYPE 5; EPISODIC ATAXIA TYPE 6; EPISODIC ATAXIA TYPE 7; EXERCISE; GAIT; GENE MUTATION; GENE THERAPY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SCREENING; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTENSION; HYPOTHYROIDISM; INTENTION TREMOR; KIDNEY INJURY; MACHADO JOSEPH DISEASE; MUSCLE TREMOR; MUSCLE TWITCH; NEPHROGENIC DIABETES INSIPIDUS; NEPHROLITHIASIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RARE DISEASE; RASH; RNA INTERFERENCE; SEIZURE; SENSORY STIMULATION; SIDE EFFECT; SPASTICITY; SPINOCEREBELLAR DEGENERATION; STEM CELL TRANSPLANTATION; TREMOR; WEIGHT GAIN; X LINKED FRAGILE X TREMOR AND ATAXIA SYNDROME; CLASSIFICATION; FRAGILE X SYNDROME; GENETICS; MYOCLONUS EPILEPSY; REVIEW; TRINUCLEOTIDE REPEAT;

ATAXIA; FRAGILE X SYNDROME; HUMANS; MACHADO-JOSEPH DISEASE; MYOCLONIC EPILEPSIES, PROGRESSIVE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; REPRESSOR PROTEINS; SPINOCEREBELLAR ATAXIAS; TRINUCLEOTIDE REPEATS;

EID: 84859485229     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0653-2_14     Document Type: Article

References (115)

1. Matilla-Duenas A, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain 2006; 129:1357-1370.
2. Matilla-Duenas A, Sanchez I, Corral-Juan M et al. Cellular and Molecular Pathways Triggering Neurodegeneration in the Spinocerebellar Ataxias. Cerebellum 2010; 9(2):148-166.
3. Coutinho P, Sequeiros J. Clinical, genetic and pathological aspects of Machado-Joseph disease. J Genet Hum1981;29(3):203-209.
4. Matilla T, McCall A, Subramony SH et al. Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease. Ann Neurol 1995; 38(1):68-72.
5. Paulson HL. Dominantly inherited ataxias: lessons learned from Machado-Joseph disease/spinocerebellar ataxiatype 3. SeminNeurol 2007; 27(2):133-142.
6. Riess O, Rub U, Pastore A et al. SCA3: neurological features, pathogenesis and animal models. Cerebellum 2008;7(2):125-137.
7. Isozaki E, Naito R, Kanda T et al. Different mechanism of vocal cord paralysis between spinocerebellar ataxia (SCA 1 and SCA 3) and multiple system atrophy. J Neurol Sci 2002; 197(1-2):37-43.
8. Yoshizawa T, Nakamagoe K, Ueno T et al. Early vestibular dysfunction in Machado-Joseph disease detected by caloric test. J Neurol Sci 2004; 221(1-2):109-111.
9. Yeh TH, Lu CS, Chou YH et al. Autonomic dysfunction in Machado-Joseph disease. Arch Neurol 2005; 62(4):630-636.
10. Friedman JH. Presumedrapideye movement behavior disorder in Machado-Joseph disease (spinocerebellar ataxia type 3). Mov Disord 2002; 17(6):1350-1353.
11. Friedman JH, Fernandez HH, Sudarsky LR. REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3). Mov Disord 2003; 18(12):1520-1522.
12. Schols L, Haan J, Riess O et al. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause ofrestless legs syndrome? Neurology 1998; 51(6):1603-1607.
13. van Alfen N, Sinke RJ, Zwarts MJ et al. Intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype. Ann Neurol 2001; 49(6):805-807.
14. Sequeiros J, Coutinho P. Epidemiology and clinical aspects of Machado-Joseph disease. Adv Neurol 1993; 61:139-153.
15. Rosenberg RN. Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov Disord 1992; 7(3):193-203.
16. Coutinho P, Andrade C. Autosomal dominant system degeneration in Portuguese families of the Azores Islands: a new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology 1978; 28:703-709.
17. YamadaS, Nishimiya J, NakajimaT et al. Linear high intensity area along the medial margin of the internal segment of the globus pallidus in Machado-Joseph disease patients. J Neurol Neurosurg Psychiatry 2005; 76(4):573-575.
18. Rub U, De Vos RA, Schultz C et al. Spinocerebellar ataxia type 3 (Machado-Joseph disease): severe destruction of the lateral reticular nucleus. Brain 2002; 125:2115-2124.
19. Rub U, Del Turco D, Del Tredici K et al. Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxiatype 3 (SCA3) patient and its clinical relevance. Brain 2003; 126:2257-2272.
20. Rub U, Gierga K, Brunt ER et al. Spinocerebellar ataxias types 2 and 3: degeneration of the precerebellar nuclei isolates the three phylogenetically defined regions of the cerebellum. J Neural Transm 2005; 112(11):1523-1545.
21. Rub U, de Vos RA, Brunt ER et al. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol2006; 16(3):218-227.
22. Rub U, Seidel K, Ozerden I et al. Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res Rev 2007; 53(2):235-249.
23. Rub U, Brunt ER, Gierga K et al. The nucleus raphe interpositus in spinocerebellar ataxia type 3 (Machado-Joseph disease). J Chem Neuroanat 2003; 25(2):115-127.
24. Tsuji S. Dentatorubral-pallidoluysian atrophy: clinical aspects and molecular genetics. Adv Neurol 2002; 89:231-239.
25. Tsuji S. Dentatorubral-pallidoluysian atrophy In: Pagon R, Bird T, Dolan C et al, eds. GeneReviews [Internet]. Seattle (WA): University ofWashington, Seattle, 2010.
26. Koide R, Onodera O, Ikeuchi T et al. Atrophy of the cerebellum and brainstem in dentatorubralpallidoluysian atrophy. Influence of CAG repeat size on MRI findings. Neurology 1997; 49(6):1605-1612.
27. Jacquemont S, Hagerman RJ, Leehey M et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical and neuroimaging correlates. Am J Hum Genet 2003; 72(4):869-878.
28. Jacquemont S, Hagerman RJ, Hagerman PJ et al. Fragile-X syndrome and fragile X-associated tremor/ ataxia syndrome: two faces ofFMR1. Lancet Neurol 2007; 6(1):45-55.
29. Cohen S, Masyn K, Adams J et al. Molecular and imaging correlates of the fragile X-associated tremor/ ataxia syndrome. Neurology 2006; 67(8):1426-1431.
30. Soontarapornchai K, Maselli R, Fenton-Farrell G et al. Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol 2008; 65(4):495-498.
31. Leehey MA, Berry-Kravis E, Min SJ et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 2007; 22(2):203-206.
32. Jen JC, Graves TD, Hess EJ et al. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 2007; 130:2484-2493.
33. Jen JC. Hereditary episodic ataxias. Ann N Y Acad Sci 2008; 1142:250-253.
34. Imbrici P, Gualandi F, D'Adamo MC et al. A novel KCNA1 mutation identified in an Italian family affected by episodic ataxiatype 1. Neuroscience 2008; 157(3):577-587.
35. Eunson LH, Rea R, Zuberi SM et al. Clinical, genetic and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol 2000; 48(4):647-656.
36. Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology 2004; 62(1):17-22.
37. Bertholon P, Chabrier S, Riant F et al. Episodic ataxia type 2: unusual aspects in clinical and genetic presentation. Special emphasis in childhood. J Neurol Neurosurg Psychiatry 2009; 80(11):1289-1292.
38. Jodice C, Mantuano E, Veneziano L et al. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum Mol Genet 1997; 6(11):1973-1978.
39. Jen JC, Yue Q, Karrim J et al. Spinocerebellar ataxia type 6 with positional vertigo and acetazolamide responsive episodic ataxia. J Neurol Neurosurg Psychiatry 1998; 65(4):565-568.
40. 2+ channel gene CACNL1A4. Cell 1996; 87(3):543-552.
41. Riant F, Lescoat C, Vahedi K et al. Identification of CACNA1A large deletions in four patients with episodic ataxia. Neurogenetics 2010; 11(1):101-106.
42. Steckley JL, Ebers GC, Cader MZ et al. An autosomal dominant disorder with episodic ataxia, vertigo and tinnitus. Neurology 2001; 57(8):1499-1502.
43. Cader MZ, Steckley JL, Dyment DA et al. A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia. Neurology 2005; 65(1):156-158.
44. Farmer TW, Mustian VM. Vestibulocerebellar ataxia. A newly defined hereditary syndrome with periodic manifestations. ArchNeurol 1963; 8:471-480.
45. Small KW, Pollock SC, Vance JM et al. Ocular motility in North Carolina autosomal dominant ataxia. JNeuroophthalmol 1996; 16(2):91-95.
46. Damji KF, Allingham RR, Pollock SC et al. Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. Arch Neurol 1996; 53(4):338-344.
47. Escayg A, De Waard M, Lee DD et al. Coding and noncoding variation of the human calcium-channel beta4- subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet 2000; 66(5):1531-1539.
48. Jen JC, Wan J, Palos TP et al. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia and seizures. Neurology 2005; 65(4):529-534.
49. de Vries B, Mamsa H, Stam AH et al. Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake. Arch Neurol 2009; 66(1):97-101.
50. Kerber KA, Jen JC, Lee H et al. A new episodic ataxia syndrome with linkage to chromosome 19q13. Arch Neurol 2007; 64(5):749-752.
51. Meijer IA, Hand CK, Grewal KK et al. A locus for autosomal dominant hereditary spastic ataxia, sax1, maps to chromosome 12p13. Am J Hum Genet 2002; 70(3):763-769.
52. Melberg A, Hetta J, Dahl N et al. Autosomal dominant cerebellar ataxia deafness and narcolepsy. J Neurol Sci 1995; 134(1-2):119-129.
53. Melberg A, Dahl N, Hetta J et al. Neuroimaging study in autosomal dominant cerebellar ataxia, deafness andnarcolepsy. Neurology 1999; 53(9):2190-2192.
54. Trudeau MM, Dalton JC, Day JW et al. Heterozygosity for a protein truncation mutation of sodium channel SCN8Ainapatient with cerebellar atrophy, ataxiaandmental retardation. JMed Genet 2006; 43(6):527-530.
55. Genis D, Ferrer I, Sole JV et al. A kindred with cerebellar ataxia and thermoanalgesia. J Neurol Neurosurg Psychiatry 2009; 80(5):518-523.
56. Ogawa M. Pharmacological treatments of cerebellar ataxia. Cerebellum 2004; 3(2):107-111.
57. Manto M, Marmolino D. Cerebellar ataxias. Curr Opin Neurol 2009; 22(4):419-429.
58. Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F et al. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord 2009; 24(8):1111-1124.
59. Nakamura K, Yoshida K, Miyazaki D et al. Spinocerebellar ataxia type 6 (SCA6): clinical pilot trial with gabapentin.JNeurol Sci 2009; 278(1-2):107-111.
60. Woods BT, Schaumburg HH. Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia. A unique and partially treatable clinicopathological entity. J Neurol Sci 1972; 17(2):149-166.
61. Tuite PJ, Rogaeva EA, St George-Hyslop PH et al. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 1995; 38(4):684-687.
62. Buhmann C, Bussopulos A, Oechsner M. Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord 2003; 18(2):219-221.
63. Kanai K, Kuwabara S, Arai K et al. Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 2003; 126:965-973.
64. Pineda M, Montero R, Aracil A et al. Coenzyme Q(10)-responsive ataxia: 2-Year-treatment follow-up. Mov Disord 2010; 25(9):1262-8.
65. Lock RJ, Tengah DP, Williams AJ et al. Cerebellar ataxia, peripheral neuropathy, "gluten sensitivity" and anti-neuronal autoantibodies. Clin Lab 2006; 52(11-12):589-592.
66. Nanri K, Okita M, Takeguchi M et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med 2009; 48(10):783-790.
67. Xia H, Mao Q, Eliason SL et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model ofspinocerebellar ataxia. Nat Med 2004; 10(8):816-820.
68. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005; 6(1):11-22.
69. Chan HY, Warrick JM, Gray-Board GL et al. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 2000; 9(19):2811-2820.
70. Heiser V, Scherzinger E, Boeddrich A et al. Inhibition ofhuntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci USA 2000; 97(12):6739-6744.
71. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003; 421(6921):373-379.
72. Yoshida H, Yoshizawa T, Shibasaki F et al. Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol Dis 2002; 10(2):88-99.
73. Tanaka M, Machida Y, Niu S et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model ofHuntington disease. Nat Med 2004; 10(2):148-154.
74. Heiser V, Engemann S, Brocker W et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors ofHuntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci USA 2002; 99:16400-16406.
75. Zhang X, Smith DL, Meriin AB et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci USA 2005; 102(3):892-897.
76. Kieran D, Kalmar B, Dick JR et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004; 10(4):402-405.
77. Rimoldi M, Servadio A, Zimarino V. Analysis of heat shock transcription factor for suppression of polyglutamine toxicity. Brain Res Bull 2001; 56(3-4):353-362.
78. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004; 23(16):2907-2918.
79. Dedeoglu A, Kubilus JK, Jeitner TM et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002; 22(20):8942-8950.
80. KarpujMV, Becher MW, Springer JE et al. Prolonged survival and decreased abnormal movements in transgenic model ofHuntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002; 8(2):143-149.
81. Shults CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003; 10(19):1917-1921.
82. Ryu H, Rosas HD, Hersch SM et al. The therapeutic role of creatine in Huntington's disease. Pharmacol Ther2005; 108(2):193-207.
83. Keene CD, Rodrigues CM, Eich T et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 2002; 99(16):10671-10676.
84. Ravikumar B, Vacher C, Berger Z et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions infly andmouse models ofHuntington disease. Nat Genet 2004; 36(6):585-595.
85. Menzies FM, Rubinsztein DC. Broadening the therapeutic scope for rapamycin treatment. Autophagy 2010; 6(2):286-287.
86. Sanchez I, Xu CJ, Juo P et al. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999; 22(3):623-633.
87. Ona VO, Li M, Vonsattel JP et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999; 399(6733):263-267.
88. ChenM, OnaVO, Li Met al. Minocycline inhibits caspase-1 andcaspase-3 expression and delays mortality in a transgenic mouse model ofHuntington disease. Nat Med 2000; 6(7):797-801.
89. Lesort M, Lee M, Tucholski J et al. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003; 278(6):3825-3830.
90. Gauthier S. Dimebon improves cognitive function in people with mild to moderate Alzheimer's disease. Evid Based Ment Health 2009; 12(1):21.
91. Liu J, Tang TS, Tu H et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2.JNeurosci 2009; 29(29):9148-9162.
92. Mestre T, Ferreira J, Coelho MM et al. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009; 3:CD006455.
93. Ristori G, Romano S, Visconti A et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlledpilottrial. Neurology 2010; 74(10):839-845.
94. Bordet T, Buisson B, Michaud M et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007; 322(2):709-720.
95. Strupp M, Kalla R, Glasauer S et al. Aminopyridines for the treatment of cerebellar and ocular motor disorders. Prog Brain Res 2008; 171:535-541.
96. Alvina K, Khodakhah K. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 2010; 30(21):7258-7268.
97. Tsunemi T, Ishikawa K, Tsukui K et al. The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia. J Neurol Sci 2010; 292(1-2):81-84.
98. Dokmanovic M, Marks PA. Prospects: Histone deacetylase inhibitors. J Cell Biochem 2005; 96(2):293-304.
99. Thomas EA, Coppola G, Desplats PA et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 2008; 105(40):15564-15569.
100. Naoi M, Maruyama W, Yi H et al. Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm 2009.
101. Gatchel JR, Watase K, Thaller C et al. The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Proc Natl Acad Sci USA 2008; 105(4):1291-1296.
102. Fernandez AM, Carro EM, Lopez-Lopez C et al. Insulin-like growth factor I treatment for cerebellar ataxia: Addressing a common pathway in the pathological cascade? Brain Res Rev 2005; 50(1):134-141.
103. Leinninger GM, FeldmanEL. Insulin-like growth factors in the treatment of neurological disease. Endocr Dev 2005; 9:135-159.
104. Chintawar S, Hourez R, Ravella A et al. Grafting neural precursor cells promotes functional recovery in an SCA1 mouse model.JNeurosci 2009; 29(42):13126-13135.
105. Gage FH. Neurogenesis in the adult brain. J Neurosci 2002; 22(3):612-613.
106. Klein A, Boltshauser E, Jen J et al. Episodic ataxia type 1 with distal weakness: a novel manifestation of a potassium channelopathy. Neuropediatrics 2004; 35(2):147-149.
107. Griggs RC, Moxley RT, 3rd, Lafrance RA et al. Hereditary paroxysmal ataxia: response to acetazolamide. Neurology 1978; 28(12):1259-1264.
108. Boel M, Casaer P. Familial periodic ataxiaresponsive to flunarizine. Neuropediatrics 1988; 19(4):218-220.
109. Strupp M, Kalla R, Dichgans M et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004; 62(9):1623-1625.
110. Alvina K, Khodakhah K. KCa channels as therapeutic targets in episodic ataxia type-2. J Neurosci 2010; 30(21):7249-7257.
111. Kinali M, Jungbluth H, Eunson LH et al. Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia. Neuromuscul Disord 2004; 14(10):689-693.
112. De Marcos FA, Ghizoni E, Kobayashi E et al. Cerebellar volume and long-term use ofphenytoin. Seizure 2003; 12(5):312-315.
113. Strupp M, Schuler O, Krafczyk S et al. Treatment of down-beat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 2003; 61(2):165-170.
114. Ilg W, Synofzik M, Brotz D et al. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 2009; 73(22):1823-1830.
115. Missaoui B, Thoumie P. How far do patients with sensory ataxia benefit from so-called "proprioceptive rehabilitation"? Neurophysiol Clin 2009; 39(4-5):229-233.